CAI Caris Life Sciences, Inc. Insider Trading

Director Jon Halbert purchases 68,000 shares of Caris Life Sciences at $14.56; now holds 704,598 shares (+10.7%).

Jon Halbert, a director of Caris Life Sciences, acquired 68,000 shares at $14.56 on 2026-05-15, expanding his holdings by 10.7% to 704,598 shares total. The transaction occurred at a price that sits near the lower end of the 52-week range ($14.19–$42.50) and represents a $990,080 commitment. The company reported Revenue $216,174,000.00 for the latest quarter and Annual revenue growth (FY vs prior FY) of +97.0%, but remains unprofitable with Net income of $-510,000.00 and a full-year negative net income, reflected in an elevated P/E of 141.58. The stock is currently -60.0% from its 52-week high, suggesting the purchase occurred during a period of material price weakness relative to recent trading history. This substantial share acquisition by a director during a period of depressed valuation and significant revenue expansion, though from an unprofitable base, merits monitoring of the underlying business trajectory and capital allocation decisions.

Director Vacirca Jeff L purchases 31,050 shares at $16.15, doubling his stake while stock trades well below 52-week highs.

Director Jeff Vacirca is making his second open-market purchase in the past two years, this time acquiring a substantial block that nearly doubles his holdings. The purchase occurs while the stock trades significantly below its 52-week high, having declined notably over the past three months. Vacirca's prior purchase history shows strong subsequent returns, with all prior buys resulting in gains within 90 days, suggesting he has demonstrated timing acuity on previous entries. However, the company remains unprofitable despite strong revenue growth, creating a mixed backdrop: the business is expanding rapidly, but profitability remains elusive. For a director without officer-level operational responsibilities to commit this level of capital at a depressed price point is noteworthy, though the unprofitable fundamentals suggest he is buying into a turnaround story rather than capitalizing on an already-stable business.

Power Luke Thomas sold 62,250 shares at blended avg $26.58 via pre-arranged 10b5-1 plan (scheduled)

Power Luke Thomas executed 2 separate sales totaling 62,250 shares for $1,654,461.30 on 2025-12-11 at blended average price of $26.58, reducing his holdings from 161,821 shares to 99,571 shares (-38.5% of pre-transaction holdings). This transaction was conducted pursuant to a pre-arranged 10b5-1 trading plan adopted on 2025-08-19, meaning the timing and volume were scheduled in advance rather than discretionary responses to current market conditions. As a prearranged disposition, this sale provides limited insight into insider conviction about current valuation or near-term prospects; it reflects predetermined portfolio management mechanics rather than a contemporaneous judgment about the company.

Caris Life Sciences insider buys 4,184 shares at $24.09; stock down 36.9% from 52-week high but prior buy at CAI showed +59.2% 90-day return.

Denton John Russel purchased 4,184 shares of CAI at $24.09, increasing his holdings by 83.7% to 9,184 shares post-transaction. The timing follows a meaningful price decline: the stock trades at $24.80 (36.9% below its 52-week high of $39.30) and has fallen 18.6% over the past 30 days and 23.6% over 90 days. Notably, Russel's prior purchase at CAI on 2025-06-20 delivered a 59.2% return over 90 days, and his cross-ticker track record shows 100% win rate on buys with an average 90-day return of 59.2%. The company's fundamentals remain intact with revenue of $216.8M and net income of $24.3M in the latest quarter against a $7.0B market cap. This acquisition in a depressed environment mirrors his demonstrated pattern of well-timed accumulation at this ticker.

CAI President Spetzler bought 400 shares at $23.85 on 2025-11-07; stock down 18.6% in 30 days, 23.6% in 90 days.

David Baxley Spetzler, President of Caris Life Sciences, purchased 400 shares for $9,540.00 at $23.85 on 2025-11-07, a modest addition to his 460.4K-share baseline position. The current price of $24.80 shows the stock has recovered slightly from the transaction price, but broader momentum is negative: the stock is down 18.6% over the past 30 days and down 23.6% over the past 90 days, trading 36.9% below its 52-week high of $39.30. The company maintains positive fundamentals with $24.3M in net income against $216.8M in quarterly revenue. This small-scale purchase in a weak price environment, combined with the insider's substantial pre-existing stake of 460.4K shares, provides a limited signal without additional context on the executive's broader trading pattern or board-wide activity.

Insider Denton John Russel bought 7,500 shares of CAI at $21.00 on 2025-06-20, raising holdings to 123,591 shares.

Denton John Russel purchased 7,500 shares at $21.00, increasing his position by 6.5% to 123,591 shares post-transaction. The stock is trading at $25.94 as of 2025-06-23, just 3 trading days post-purchase. Caris Life Sciences is a recent listing, so historical price comparisons are not yet meaningful. The purchase represents a direct capital commitment, but without longer-term trading history or fundamental context, the materiality of this transaction relative to the insider's portfolio and the company's trajectory remains to be established.

Brille bought 30,000 shares of CAI at $21.00 (total $630,000); holdings increased 22.7% to 162,428 shares post-purchase.

Brille Brian J purchased 30,000 shares at $21.00 on 2025-06-20, just 3 trading days before the current market price of $25.94, representing a material addition to his stake of 22.7% relative to pre-transaction holdings. The timing is proximate to the company's recent listing, and the substantial purchase size ($630,000.00 in absolute terms) and proportional increase suggests a meaningful commitment during the early post-IPO period. The open-market purchase nature of the transaction and the size relative to prior holdings warrant investor attention to potential insider conviction, though the limited post-purchase price history constrains assessment of broader strategic positioning.